Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Immunopathology and Immunotherapy of Hodgkin Lymphoma Publisher



Ebadi M1 ; Zeng Y2 ; Gkotzamanidou M3 ; Rezaei N4, 5, 6
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Immunology, Molecular Immunology Research Center, Children’s Medical Center, Tehran University of Medical Sciences, Tehran, 14194, Iran
  2. 2. Department of Pediatrics, Steele Children’s Research Center, University of Arizona, Tucson, 85724, AZ, United States
  3. 3. Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, 02215, MA, United States
  4. 4. Research Center for Immunodeficiencies, Children’s Medical Center, Pediatrics Center of Excellence, Tehran University of Medical Sciences, Tehran, 14194, Iran
  5. 5. Department of Immunology, Molecular Immunology Research Center, School of Medicine, Tehran University of Medical Sciences, Tehran, 14194, Iran
  6. 6. Universal Scientific Education and Research Network (USERN), Tehran, Iran

Source: Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors Published:2015


Abstract

Immunotherapy has led to promising results in the treatment of malignancies in recent decades. In view of the suboptimal results obtained by applying other treatment modalities in the treatment of Hodgkin lymphoma (HL), attention has been drawn to immunotherapy as an efficient alternative or complement therapy. This chapter seeks to discuss a wide spectrum of immunotherapeutic approaches, from initial monoclonal antibodies to novel techniques developed in recent years, which are still at their infancy. Since correct understanding of the underlying immunopathology seems inevitable in efficient immunotherapy and the development of future techniques, a brief description with the emphasis on suitable targets for immunotherapy is given before discussing various immunotherapies. © Springer-Verlag Berlin Heidelberg 2015.
1. Immunopathology and Immunotherapy of Hodgkin Lymphoma, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
2. Immunopathology and Immunotherapy of Non-Hodgkin Lymphoma, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2015)
3. Immunopathology and Immunotherapy of Non-Hodgkin Lymphoma, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
7. Car-Nk Cells: A Promising Cellular Immunotherapy in Lymphoma, Expert Opinion on Biological Therapy (2023)
Experts (# of related papers)